Silexion Therapeutics Corp — Form 8-K
Filed July 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
On July 20, 2026, Silexion shareholders passed an ordinary resolution to increase authorized share capital from US$796,500 (5.9M shares at $0.135 par) to US$2,146,500 (15.9M shares at $0.135 par), creating 10M new authorized ordinary shares. The par value per share remains US$0.135. This expands the authorized capital pool by 169% but does not indicate actual issuance.
Why this rating
Authorized-share increase is routine governance; enables future fundraising/dilution but does not immediately impact cash, assets, or operations. Neutral pending actual use.
See more from July 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.